Analyst Reports

Monday, August 18, 2014

Alchemia plans to report top line results for its pivotal Phase III trial in metastatic colorectal cancer this quarter. We are confident of a successful read out and we have run some sensitivities on the impact on our price target. In this note we review a number of the existing treatments and other compounds in development and reflect on the clinical trial so far.

Tuesday, July 29, 2014

Thomas Duthy (PhD MBA) from Taylor Collison, Sharebrokers and Investment Advisors, has prepared a detailed report on Alchemia. Titled: Strong upside if Phase 3 HA-IRI Delivers in Colorectal Cancer.

Tuesday, July 1, 2014

Select Equities has prepared a stock research note on Alchemia Ltd (ACL). The research focuses on ACL's pivotal Phase III HA-Irinotecan trial, the results of which are expected to be announced before the end of 3Q CY14.

Monday, June 30, 2014

We look in depth at a small cap which is fully funded and has a massive potential pay day literally around the corner. We believe that this biotech could more than triple if it delivers positive final stage clinical trial results. Alchemia (ACL)has already delivered subscribers a return of just over 40 per cent since we tipped it just over 12 months ago. We hope it will do much better than that in the coming months.
Click on this link https://undertheradar.worldsecuresystems.com/six-weeks-free which offers shareholders a six week free trial to www.undertheradarreport.com.au (normally its 30 days).

Wednesday, February 19, 2014

Analyst increase Alchemia's target share price from A$0.71 to A$0.82. Although royalty income received from fondaparinux was lower than expected, the main game is the Phase III read out from the colorectal cancer program, expected in 2QCY14

Pages